Table 2.

Correlations among molecular and clinicopathologic features: For the patients with PDA, mutated NGS markers (>3) are listed in red text, while altered IHC markers (>4) are listed in orange text. Using Fisher’s exact test association testing was performed to identify significant variables that correlated between the clinical and molecular variables in patients with PDA. These significant variables are shown on the table. LVI: lympho-vascular invasion, GERD: gastroesophageal reflux disease.

Variable 1	Variable 2	p value	Odds ratio
LVI present	Positive lymph node, N1	6.50E-07	73.9
Hyperlipidemia	Hypertension	3.60E-04	10.9
IHC: ERCC1	IHC: TS	5.90E-04	14.4
NGS: CDKN2A	NGS: CDKN2B	9.10E-04	Infinity
GERD	Hyperlipidemia	0.0023	8.1
IHC: PTEN	NGS: CDKN2A	0.0027	0
Hypertension	NGS: DNMT3A	0.0033	Infinity
NGS: CDKN2A	NGS: CDKN2ARF	0.0033	Infinity
GERD	Hypertension	0.0035	6.9
Metastatic presentation	NGS: BRCA2	0.0067	64
Gender, male	IHC: TS	0.0097	0.2
NGS: CDKN2ARF	NGS: SMAD4	0.011	15.7
Hypertension	Obesity	0.011	Infinity
Family cancer history	Size, > 3 cm	0.014	0.2
NGS_DNMT3A	Size, > 3 cm	0.018	Infinity
Grade 3/4	IHC: MET	0.019	0
Age >66	Recent smoker	0.019	0.2
Age >66	NGS: CDKN2ARF	0.02	Infinity
NGS: BRCA2	Location, pancreatic head	0.021	0
IHC: TS	Obesity	0.024	Infinity
Location, pancreatic head	Pancreatitis	0.027	6
Family cancer history	IHC: ERCC1	0.028	8
Diabetes	Hypertension	0.028	4.2
NGS: CDKN2A	NGS: TP53	0.031	5.4
Diabetes	IHC: PTEN	0.031	0.1
Arthritis	Obesity	0.034	12.1
Hyperlipidemia	NGS: DNMT3A	0.034	9.9
Family cancer history	Metastatic presentation	0.036	18.4
Age >66	IHC: PD1	0.039	0.1
Arthritis	Hyperlipidemia	0.042	4.1
NGS: TP53	Location, pancreatic head	0.044	4
Grade 3/4	NGS: DNT3A	0.047	8.7
IHC: PD1	NGS: CDKN2B	0.048	11.2
Age >66	IHC: PTEN	0.048	Infinity
IHC: TUBB3	NGS: ARID1A	0.049	0
Grade 3/4	LVI present	0.05	5.2